U.S. stock market midday update: HCW Biologics up 67.78%

U.S. Stock Market Midday Update HCW Biologics rose 67.78%, with increased trading volume. Based on recent important news: On August 25, the company demonstrated success in its IND-enabled study of the pembrolizumab-based immune checkpoint inhibitor for solid tumors, activating immune cells and promoting their infiltration, driving the stock price up. On August 25, the Chinese stock market was severely undervalued, with investors showing strong enthusiasm for buying, pushing the overall market up. On August 23, the futures market favored bulls, with strong signals of capital inflow supporting a rebound in stock prices. Stocks with High Trading Volume in the Industry OSR rose 126.21%, with a trading volume of 153 million. Based on recent important news: On July 8, OSR Holdings obtained a $80 million equity credit line, enhancing the company's financial strength and driving the stock price up. On July 25, OSL Group announced the completion of a $300 million equity financing, with the market optimistic about its expansion plans, boosting related stocks. On July 22, Opendoor Technologies resumed trading and rose 10%, indicating a recovery in market confidence in tech stocks. ESSA Pharmaceuticals fell 59.18%, with increased trading volume. Based on recent key news: On July 26, EDESA BIOTECH INC submitted a mixed shelf registration statement of up to $150 million to the U.S. Securities and Exchange Commission, raising concerns in the market about the company's future financing and equity dilution, leading to a significant drop in stock price. On July 18, Federal Pharmaceuticals announced a proposed placement of 156 million new shares, with the placement price discounted by about 7.93% compared to the previous day's closing price, triggering market concerns about equity dilution, causing the stock price to fall. On July 4, a block trade occurred at Yaoyigou, with the transaction price discounted by 16.99% compared to the closing price of that day, leading to negative market expectations for the company's stock price, resulting in a decline. Argenx rose 5.20%, with a trading volume of $55.28 million. Based on recent important news: On August 25, Argenx announced positive top-line results for Vyvgart in AChR-Ab negative gMG patients, planning to submit an SBLA to expand the label, driving the stock price up by 5.20%. On August 25, Vyvgart Hytrulo pre-filled syringes were approved for self-injection, enhancing market confidence. On August 25, long-term data for Vyvgart showed sustained disease control in gMG and CIDP, with good safety, further supporting the rise in stock price. Stocks with High Market Capitalization in the Industry AbbVie rose 0.07%, with increased trading volume. Based on recent key news: On August 22, AbbVie announced that its alopecia treatment drug Rinvoq achieved its primary goals in two key late-stage trials, significantly increasing the rate of hair regrowth on patients' scalps, which drove the stock price up. On August 25, AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' antidepressant for $1.2 billion, expanding its psychiatry drug pipeline and further boosting market confidence. On August 24, analysts predicted that AbbVie's Skyrizi and Rinvoq sales would reach $31 billion, exceeding previous expectations and enhancing investor confidence in the company's future growth